← Search

Journal of Financial Economics Vol. 67 No. 3 2003

Do equity financing cycles matter? evidence from biotechnology alliances

Josh Lerner1,2; Hilary Shane3; Alexander C. Tsai4,5

1 National Bureau of Economic Research · 2 Harvard University · 3 Millennium Engineering and Integration (United States) · 4 Case Western Reserve University · 5 Western University of Health Sciences

Abstract

In periods characterized by diminished public market financing, small biotechnology firms appear to be more likely to fund R&D through alliances with major corporations rather than with internal funds (raised through the capital markets). We consider 200 alliance agreements entered into by biotechnology firms between 1980 and 1995. Agreements signed during periods of limited external equity financing are more likely to assign the bulk of the control to the larger corporate partner, and are significantly less successful than other alliances. These agreements are also disproportionately likely to be renegotiated if financial market conditions subsequently improve.

DOI
10.1016/s0304-405x(02)00256-8
Volume
67
Issue
3
Pages
411-446
Language
en
Sources
openalex crossref bibtex:phds-export.bib

Cite